AGP Picks
View all

Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

News originally published by

GlobeNewswire

Nes-Ziona, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with certain investors for the purchase and sale, in a registered direct offering, of an aggregate of $7,500,000 of the Company’s ordinary shares (or pre-funded warrants in lieu thereof), together with accompanying ordinary warrants to purchase up to an equal number of ordinary shares, at a combined purchase price of $1.315 per ordinary share (or $1.314 per pre-funded warrant) and accompanying ordinary warrant, representing a premium of 10.5% to the Nasdaq official closing price of the ordinary shares on November 13, 2026 (the “Registered Offering”). The ordinary warrants will have an exercise price of $1.578 per share, will be exercisable immediately upon issuance, and will expire three years from the initial closing date. The pre-funded warrants will have an exercise price of $0.001 per share, will be exercisable immediately upon issuance, and will not expire until exercised in full.

The Registered Offering will be consummated in a series of closings. At the initial closing, which is expected to occur on or about November 17, 2026, subject to the satisfaction of customary closing conditions, the investors will purchase an aggregate of $500,000 of securities. The investors have also irrevocably committed, subject only to the continued listing of the ordinary shares on Nasdaq or another U.S. national securities exchange, to purchase an additional aggregate of $700,000 of securities at each of ten subsequent monthly closings, commencing on December 1, 2026, and ending on or about September 1, 2027, for an aggregate of $7,000,000, at the same price and on the same terms as those applicable to the initial closing. Certain of the subsequent closings may be postponed until the Company’s receipt of shareholder approval of an increase in its authorized share capital, and any subsequent closing may be postponed if the Company’s registration statement or prospectus is not then available. The purchase price may be paid in U.S. dollars, USDT, or a combination thereof.

The aggregate gross proceeds to the Company from the Registered Offering are expected to be approximately $7.5 million, assuming all closings are consummated, before deducting offering expenses payable by the Company and excluding any proceeds from the exercise of the ordinary warrants. If the ordinary warrants issued in the Registered Offering are exercised in full for cash, the Company would receive additional gross proceeds of approximately $9.0 million; however, no assurance can be given that any of the ordinary warrants will be exercised. The Company intends to use the net proceeds from the Registered Offering for clinical, regulatory, manufacturing, and research and development activities; potential acquisitions and in-licensing; and other general corporate purposes. The Registered Offering is being made directly by the Company, without a placement agent, underwriter, broker or dealer, and no placement agent fees will be payable.

The ordinary shares, pre-funded warrants and ordinary warrants offered in the Registered Offering, and the ordinary shares issuable upon exercise of such warrants, are being offered by the Company pursuant to a shelf registration statement on Form F-3 (File No. 333-286956) previously filed with the Securities and Exchange Commission (the “SEC”), which became effective on May 12, 2025. The Registered Offering is being made only by means of a prospectus supplement and accompanying base prospectus that form a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the Registered Offering will be filed with the SEC and, when filed, will be available on the SEC’s website at www.sec.gov. Additional information regarding the securities described above and the terms of the transactions will be included in a Report on Form 6-K to be filed by the Company with the SEC.

In connection with the transactions, the Company has also agreed to pay to certain investors that meet a minimum subscription threshold, subject to the terms and conditions of the securities purchase agreement, (i) 5% of upfront, down, milestone and royalty payments received by the Company or its subsidiaries during the five years following execution, from license, collaboration, partnership, co-development, co-commercialization, distribution, supply and similar commercial transactions relating to its product candidates that are entered into during the period commencing upon the Company’s receipt of the full $7.5 million subscription amount and ending 24 months following the date of the securities purchase agreement, and (ii) 5% of the proceeds paid to the Company or its shareholders from any sale, exclusive license or other disposition of the Company’s clinical assets during such 24-month period, subject to any required shareholder approval. An investor’s right to receive such payments will be forfeited if it fails to fund at least $850,000 of that aggregate subscription amount under the securities purchase agreement.

Greenberg Traurig, P.A. and FISCHER (FBC & Co.) are serving as legal counsel to Enlivex.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

ABOUT ENLIVEX

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the expected timing and consummation of the initial closing and the subsequent closings of the Registered Offering; the anticipated gross proceeds from, and the intended use of proceeds of, the Registered Offering; the potential exercise of the ordinary warrants; the Company’s ability to obtain shareholder approval of an increase in its authorized share capital; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, risks related to market conditions and the satisfaction of closing conditions for the Registered Offering; the risk that one or more investors fail to fund their commitments at the subsequent closings; the risk that the required shareholder approval is not obtained on a timely basis or at all; the risk of failure to realize the anticipated benefits of the Registered Offering and the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Times Reporter of Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.